Eidos Therapeutics (FRA:6MX) Total Liabilities : €32.68 Mil (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Total Liabilities?

Eidos Therapeutics's Total Liabilities for the quarter that ended in Sep. 2020 was €32.68 Mil.

Eidos Therapeutics's quarterly Total Liabilities increased from Mar. 2020 (€30.54 Mil) to Jun. 2020 (€33.18 Mil) but then declined from Jun. 2020 (€33.18 Mil) to Sep. 2020 (€32.68 Mil).

Eidos Therapeutics's annual Total Liabilities declined from Dec. 2017 (€16.51 Mil) to Dec. 2018 (€4.49 Mil) but then increased from Dec. 2018 (€4.49 Mil) to Dec. 2019 (€29.15 Mil).

Eidos Therapeutics Total Liabilities Historical Data

The historical data trend for Eidos Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Total Liabilities Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Total Liabilities

4.22

16.51

4.49

29.15

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Total Liabilities	Get a 7-Day Free Trial											13.57	29.15	30.54	33.18	32.68

Eidos Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eidos Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2019 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.387	+	(18.633	+	1.134
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	29.15

Total Liabilities	=	Total Assets (A: Dec. 2019 )	-	Total Equity (A: Dec. 2019 )
	=	183.438	-	154.284
	=	29.15

Eidos Therapeutics's Total Liabilities for the quarter that ended in Sep. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.739	+	(17.717	+	3.226
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	32.68

Total Liabilities	=	Total Assets (Q: Sep. 2020 )	-	Total Equity (Q: Sep. 2020 )
	=	136.987	-	104.305
	=	32.68

Eidos Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (FRA:6MX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Eidos Therapeutics (FRA:6MX) Headlines

No Headlines